Subscribe To

Price Alert Latest News Economic Calendar News

VRDN / Why Viridian Therapeutics Is One Of My 2023 Top Picks

Viridian was one of my top picks in 2022 and it made the 2023 list again. VRDN-001 data continue to impress and Viridian looks well-positioned to disrupt the thyroid eye disease market later this decade. Read More

Demo Live Account See Partner Details

Content Topics

Viridian

Therapeutics

2023

Picks

Stock

VRDN

Posted: Jan 25 2023, 13:14

Author Name: Seeking Alpha

VRDN News

By Zacks Investment Research
October 31, 2023

Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?

Viridian Therapeutics, Inc. (VRDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate

By Zacks Investment Research
August 8, 2023

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.26. This comp

By Seeking Alpha
July 13, 2023

Viridian: Despite Drop, Advancement Towards Phase 3 Continues

There were positive results achieved from Viridian Therapeutics, Inc. phase 1/2 study using VRDN-001 for the treatment of patients with chronic thyroi

By Market Watch
July 10, 2023

Viridian stock falls more than 15% after drug study update

Shares of Viridian Therapeutics Inc. VRDN, +5.06% fell in the extended session Monday after the biotech drug maker said it was making changes to its s

By Seeking Alpha
May 13, 2023

Viridian Therapeutics, Inc. (VRDN) Q1 2023 Earnings Call Transcript

Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Louisa Stone - Manager, IR Scot

By Zacks Investment Research
May 9, 2023

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimate of a loss of $1. This compare

By Seeking Alpha
April 11, 2023

Viridian: A Second Buying Opportunity, But I Am Waiting For A Better Price

Viridian Therapeutics, Inc. has been a profitable investment for me. I am trying to get in again.

By Seeking Alpha
March 8, 2023

Viridian Therapeutics, Inc. (VRDN) Q4 2022 Earnings Conference Call

Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q4 2022 Earnings Conference Call March 8, 2023 8:00 PM ET Company Participants Louisa Stone - Manager, Inve

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.